Can Europe contain its STI surge before antimicrobial resistance narrows treatment options?
Europe’s STI surge is testing diagnostics, prevention and treatment capacity as gonorrhoea and syphilis reach record levels.
Nacubactam trial win gives Meiji Seika Pharma a stronger AMR case, but approval hurdles remain
Antibiotic resistance needs new tools. Meiji Seika Pharma’s nacubactam now has Phase III data, but regulators must judge its real-world fit.
Why Bruker’s ESCMID 2026 microbiology expansion could matter for hospital labs and infection control
Bruker expanded its microbiology portfolio at ESCMID 2026. Read what the new MALDI and outbreak tools could mean for labs and infection control.
Can Vedanta Biosciences turn microbiome therapeutics into a real prevention strategy for recurrent CDI and resistant infections?
Vedanta Biosciences unveiled VE303 and VE707 data at ESCMID 2026. Read why the microbiome strategy matters for CDI and resistant infections.
Is culture-free pneumonia testing finally viable as Pattern Bioscience nears regulatory submission
Pattern Bioscience advances rapid pneumonia diagnostics toward FDA clearance. Discover what this means for ICU care and antibiotic resistance.
Faster Candida auris identification? Thermo Fisher Scientific unveils new agar
Thermo Fisher Scientific launches chromogenic media to detect Candida auris faster. Explore what this means for labs and AMR strategy.
Sinomune to launch Almirall’s Seysara in China: Can it reshape acne treatment models?
Almirall’s Seysara gains NMPA approval for acne in China. Find out what this means for dermatology antibiotics, access, and Sinomune’s market role.
Can philanthropic capital succeed where pharma failed in Gram-negative antibiotic discovery?
Will Gr-ADI fix the broken antibiotic pipeline? Explore how Gates, Novo, and Wellcome aim to reboot AMR innovation with $60M in global grants.
How Innoviva’s NUZOLVENCE could reshape STI care and resistance strategy
Innoviva Specialty Therapeutics has received approval from the U.S. Food and Drug Administration for NUZOLVENCE (zoliflodacin), a first-in-class, single-dose oral antibiotic for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. This approval, based on the largest-ever Phase 3 clinical trial for a new treatment against Neisseria gonorrhoeae, marks the first new oral gonorrhea […]
Gonorrhea resistance crisis: Can Innoviva’s zoliflodacin rewrite treatment guidelines?
Innoviva Specialty Therapeutics has reported publication of pivotal Phase 3 data in The Lancet showing that its investigational oral antibiotic zoliflodacin was non-inferior to the current standard-of-care dual therapy for uncomplicated urogenital gonorrhea. The study, conducted in partnership with the Global Antibiotic Research & Development Partnership, or GARDP, compared a single oral dose of zoliflodacin […]